A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lin Shen, MD
Peking University Cancer Hospital & Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Recruiting
- Toi Clinical Research Llc
Cerritos, California, United States
Recruiting - Florida Cancer Specialists & Research Institute
Orlando, Florida, United States
Recruiting - Northwell Health Inc.
Manhasset, New York, United States
Recruiting - Next Oncology
Fairfax, Virginia, United States
Not, yet, recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 14 Mar 2023
- Primary completion
- 30 Jun 2025
- Completion
- 30 Sept 2025
- Last update posted
- 26 Aug 2024
- Registered enrollment
- 260
- Registry id
- NCT05830097
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.